HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (17)
  • Publications (14)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by PJWCreative
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio
April 7, 2025

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

by PJWCreative
January 13, 2025

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

by PJWCreative
December 18, 2024

HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers

by PJWCreative

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
June 24, 2020 in References

A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities

PJWCreative 0 Like Post 0 Comment
Read More

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-25 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc